CV Therapeutics Announces Four Abstracts to Be Presented at the American Heart Association Scientific Sessions 2002
Wednesday November 13, 7:01 am ET
PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) today announced that four abstracts, covering the Company's three clinical programs relating to Ranexa(TM), tecadenoson, and CVT-3146 will be presented at the American Heart Association's Scientific Sessions 2002 in Chicago, Ill., on November 17-20.
Abstract Presentations
"Anti-Anginal Efficacy of Ranolazine Addition to Beta Blocker or Calcium Antagonist Therapy in Patients with a History of Heart Failure." Sunday, November 17, 2002 from 4:00 p.m. to 6:00 p.m. CT, Hall D, McCormick Lakeside Center. Abstract poster session, poster #C67, session #59.2, abstract #102531.
"Efficacy of Ranolazine as Add-On Therapy for Chronic Angina in Elderly Patients." Sunday, November 17, 2002 from 3:45 p.m. to 4:00 p.m. CT, Room S402, McCormick Place Conference Center. Abstract oral presentation, session #49.2A, abstract #102504.
"Dose Dependent Increase in Human Coronary Blood Flow Velocity Following an IV Bolus of CVT-3146, a Novel A2A Adenosine Receptor Agonist: A Potential Agent for the Use in Pharmacological Stress Testing for Myocardial Perfusion Imaging." Tuesday, November 19, 2002 from 3:00 p.m. to 3:15 p.m. CT, Room S403, McCormick Place Conference Center. Abstract oral presentation, session #65.3, abstract #111043.
"A Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Tecadenoson in Patients with PSVT Undergoing an Electrophysiologic Study: TEMPEST (Trial to Evaluate the Management of PSVT during Electrophysiologic Study with Tecadenoson)." Wednesday, November 20, 2002 from 2:00 p.m. to 2:15 p.m. CT, Room S100A, McCormick Place Conference Center. Abstract oral presentation, late breaker session, special session XII.
For more information regarding the AHA Scientific Sessions 2002 please visit scientificsessions.org .
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has four compounds in clinical trials. Ranexa(TM) (ranolazine), the first in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is being developed for the potential treatment of chronic angina. Tecadenoson, a selective A1-adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146, a selective A2A-adenosine receptor agonist, is being developed for the potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Adentri(TM), an A1-adenosine antagonist, is being developed by our partner Biogen, Inc., for the potential treatment of acute and chronic congestive heart failure. For more information, please visit CV Therapeutics' website at cvt.com . |
